BR112023004569A2 - Formas cristalinas de um inibidor de kras g12c - Google Patents
Formas cristalinas de um inibidor de kras g12cInfo
- Publication number
- BR112023004569A2 BR112023004569A2 BR112023004569A BR112023004569A BR112023004569A2 BR 112023004569 A2 BR112023004569 A2 BR 112023004569A2 BR 112023004569 A BR112023004569 A BR 112023004569A BR 112023004569 A BR112023004569 A BR 112023004569A BR 112023004569 A2 BR112023004569 A2 BR 112023004569A2
- Authority
- BR
- Brazil
- Prior art keywords
- crystalline forms
- kras
- inhibitor
- relates
- present
- Prior art date
Links
- 229940125399 kras g12c inhibitor Drugs 0.000 title abstract 3
- PEMUGDMSUDYLHU-ZEQRLZLVSA-N 2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile Chemical compound ClC=1C=CC=C2C=CC=C(C=12)N1CC=2N=C(N=C(C=2CC1)N1C[C@@H](N(CC1)C(C(=C)F)=O)CC#N)OC[C@H]1N(CCC1)C PEMUGDMSUDYLHU-ZEQRLZLVSA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
FORMAS CRISTALINAS DE UM INIBIDOR DE KRAS G12C. A presente invenção se refere a formas cristalinas de um inibidor de KRas G12C e sal do mesmo. Em particular, a presente invenção se refere a formas cristalinas do inibidor de KRas GT2C 2-[(2S)-4-[7-(8-cloro-1-naftil)-2-[[(2S)-1-metilpirrolidin-2-il]metóxi]-6,8-di-hidro-5H-pirido[3,4-d]pirimidin-4-il]-1-(2-fluoroprop-2-enoil)piperazin-2-il]acetonitrila, composições farmacêuticas compreendendo as formas cristalinas, processos para preparação das formas cristalinas e métodos de uso das mesmas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063077553P | 2020-09-11 | 2020-09-11 | |
| US202063093673P | 2020-10-19 | 2020-10-19 | |
| PCT/US2021/049940 WO2022056307A1 (en) | 2020-09-11 | 2021-09-10 | Crystalline forms of a kras g12c inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023004569A2 true BR112023004569A2 (pt) | 2023-04-04 |
Family
ID=80629890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023004569A BR112023004569A2 (pt) | 2020-09-11 | 2021-09-10 | Formas cristalinas de um inibidor de kras g12c |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230357231A1 (pt) |
| EP (1) | EP4210833A1 (pt) |
| JP (1) | JP2023540809A (pt) |
| KR (1) | KR20230137286A (pt) |
| AU (1) | AU2021340716A1 (pt) |
| BR (1) | BR112023004569A2 (pt) |
| CA (1) | CA3190944A1 (pt) |
| CL (1) | CL2023000693A1 (pt) |
| CO (1) | CO2023004141A2 (pt) |
| IL (1) | IL301236A (pt) |
| MX (1) | MX2023002942A (pt) |
| WO (1) | WO2022056307A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022500379A (ja) * | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| WO2020055760A1 (en) * | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| AU2022268962A1 (en) | 2021-05-05 | 2023-12-14 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| AR125782A1 (es) | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | Inhibidores de ras |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10647715B2 (en) * | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| SG11202004427TA (en) * | 2017-11-15 | 2020-06-29 | Mirati Therapeutics Inc | Kras g12c inhibitors |
| KR20220091480A (ko) * | 2019-09-24 | 2022-06-30 | 미라티 테라퓨틱스, 인크. | 병용 요법 |
-
2021
- 2021-09-10 WO PCT/US2021/049940 patent/WO2022056307A1/en active Application Filing
- 2021-09-10 EP EP21867707.8A patent/EP4210833A1/en active Pending
- 2021-09-10 US US18/025,817 patent/US20230357231A1/en active Pending
- 2021-09-10 MX MX2023002942A patent/MX2023002942A/es unknown
- 2021-09-10 CA CA3190944A patent/CA3190944A1/en active Pending
- 2021-09-10 KR KR1020237012251A patent/KR20230137286A/ko unknown
- 2021-09-10 JP JP2023516126A patent/JP2023540809A/ja active Pending
- 2021-09-10 BR BR112023004569A patent/BR112023004569A2/pt unknown
- 2021-09-10 AU AU2021340716A patent/AU2021340716A1/en active Pending
- 2021-09-10 IL IL301236A patent/IL301236A/en unknown
-
2023
- 2023-03-10 CL CL2023000693A patent/CL2023000693A1/es unknown
- 2023-03-30 CO CONC2023/0004141A patent/CO2023004141A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL301236A (en) | 2023-05-01 |
| US20230357231A1 (en) | 2023-11-09 |
| MX2023002942A (es) | 2023-05-22 |
| CA3190944A1 (en) | 2022-03-17 |
| CO2023004141A2 (es) | 2023-08-28 |
| CL2023000693A1 (es) | 2023-10-20 |
| JP2023540809A (ja) | 2023-09-26 |
| AU2021340716A1 (en) | 2023-03-30 |
| WO2022056307A1 (en) | 2022-03-17 |
| KR20230137286A (ko) | 2023-10-04 |
| EP4210833A1 (en) | 2023-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023004569A2 (pt) | Formas cristalinas de um inibidor de kras g12c | |
| ATE430747T1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren | |
| BR122019010008B8 (pt) | derivados de pirimidina, seu uso, e composição e combinação farmacêuticas | |
| HN2010000653A (es) | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas quinasas b | |
| EA201290147A1 (ru) | Пирроло[2,3-d]пиримидиновые соединения | |
| GEP20156282B (en) | Compounds and compositions as protein kinase inhibitors | |
| EA201000090A1 (ru) | Тризамещенные производные пиримидина для лечения пролиферативных заболеваний | |
| AR051735A1 (es) | Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos. | |
| WO2007042786A3 (en) | 4 -heteroaryl pyrimidine derivatives and use thereof as protein kinase inhibitors | |
| EA201000092A1 (ru) | Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний | |
| ECSP066718A (es) | Derivados de pirazolo[1,5-a]pirimidin-7-il-amina para usar en el tratamiento de enfermedades dependientes de la proteina quinasa | |
| UY28946A1 (es) | Compuestos de aril-y heteroaril-alquilanina que contienen pirazol, composiciones farmacéuticas que contienen los compuestos y nuevos productos químicos intermedios | |
| TN2013000394A1 (fr) | Derives de pyrrolo [2,3-d] pyrimidine servant d'inhibiteurs de kinases apparentees a la tropomyosine | |
| GEP201706748B (en) | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors | |
| ME00012B (me) | Derivati pirimidina koji se koriste kao inhibitori pi-3 kinaza | |
| PE20150637A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| BR112012031561A2 (pt) | morfolino pirimidinas e seu uso em terapia. | |
| PL378136A1 (pl) | Pirymidyny i triazyny hamujące replikacją wirusa HIV | |
| NI201100062A (es) | Inhibidores de las enzimas de proteína cinasa activadas por mitógeno p38. | |
| CR8102A (es) | Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa | |
| ECSP077985A (es) | Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina | |
| BRPI0407306A (pt) | 1,2,4- triazinas de inibição de hiv | |
| RS54339B1 (en) | NEW ANTIMALARIAN AGENTS | |
| ECSP088973A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| EA200970669A1 (ru) | Производные 2-амино-5,7-дигидро-6н-пирроло[3,4-d]пиримидина в качестве ингибиторов hsp-90, предназначенные для лечения рака |